Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS)

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 3, 2014, Pages 355-363

  Khatri, B O ^a   Pelletier, J ^b   Kappos, L ^c   Hartung, H P ^d   Comi, G ^e   Barkhof, F ^f   Von Rosenstiel, P ^g   Meng, X ^g   Grinspan, A ^g,i   Hashmonay, R ^g   Cohen, J A ^h  

^a Wheaton Franciscan Healthcare   (United States)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NOVARTIS PHARMA AG   (Switzerland)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ TEVA PHARMACEUTICALS   (Israel)

Author keywords

Disease modifying therapy; Fingolimod; Interferon; Multiple sclerosis; Relapse rate; Sphingosine 1 phosphate receptor modulator

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER;

ADULT; ARTICLE; BRADYCARDIA; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RETINA MACULA EDEMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 84896547988     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2013.11.006     Document Type: Article

References (22)

1. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006;13:471-4. (Pubitemid 43823361)
2. Carra A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386-93. (Pubitemid 351422381)
3. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
4. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013;260:2023-32.
5. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008;71:S3-7.
6. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15:50-8.
7. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005;12:425-31. (Pubitemid 40768660)
8. Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005;252(3):iii44-50.
9. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94. (Pubitemid 26100751)
10. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
11. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97.
12. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
13. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84. (Pubitemid 43739821)
14. Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40.
15. Milanese C, Beghi E, Giordano L, La Mantia L, Mascoli N, Confalonieri P. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurol Sci 2005;26(4):S171-3. (Pubitemid 43085205)
16. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
17. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74.
18. Rio J, Tintore M, Sastre-Garriga J, Nos C, Castillo J, Tur C, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012;19:899-904.
19. Ruggieri RM, Settipani N, Viviano L, Attanasio M, Giglia L, Almasio P, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003;24:361-4. (Pubitemid 38029025)
20. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
21. Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci 2011;38:429-33.
22. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006;113:378-86. (Pubitemid 44046323)